Gene Therapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
World Journal of Gastroenterology
Adenoviral vector specifically targeted to EphA2 receptor in pancreatic cancer cells
July 9th, 2009
Pancreatic cancer is a devastating disease with poor prognosis. This warrants the development of novel therapies including gene therapy. However, clinical studies have demonstrated poor efficacy of adenoviral gene therapy because of the absence of adenoviral binding sites on pancreatic cancer cells such as the coxsackie and adenovirus receptor (CAR). Circumventing CAR-mediated entry therefore seems a promising option to improve adenoviral entry into pancreatic cancer cells and to enhance the efficacy of adenoviral vectors. A research team led by Dr. Piter J Bosma from University of Amsterdam addressed this question. Their study will be published on June 14, 2009 in the...
Source: Gene Therapy Weekly (2009-07-09)
|
